



# The effects of venlafaxine and cognitive behavioral therapy alone and combined in the treatment of co-morbid alcohol use-anxiety disorders

Domenic A. Ciraulo<sup>a,\*</sup>, David H. Barlow<sup>b</sup>, Suzy Bird Gulliver<sup>c,d</sup>, Todd Farchione<sup>b</sup>, Sandra B. Morissette<sup>c,d</sup>, Barbara W. Kamholz<sup>a,e</sup>, Katherine Eisenmenger<sup>b</sup>, Bonnie Brown<sup>b</sup>, Eric Devine<sup>a</sup>, Timothy A. Brown<sup>b</sup>, Clifford M. Knapp<sup>a</sup>

<sup>a</sup> Department of Psychiatry, Boston University School of Medicine, Boston, MA, United States

<sup>b</sup> Center for Anxiety Related Disorders, Boston University, Boston, MA, United States

<sup>c</sup> VA VISN 17 Center of Excellence for Research on Returning War Veterans, United States

<sup>d</sup> Texas Agricultural & Mechanical Health Science Center, College of Medicine, College Station, TX, United States

<sup>e</sup> Veterans Affairs Boston Healthcare System, Jamaica Plain, MA, United States

## ARTICLE INFO

### Article history:

Received 6 May 2013

Received in revised form

6 August 2013

Accepted 19 August 2013

### Keywords:

Anxiety

Alcoholism

Antidepressants

Cognitive behavioral therapy

## ABSTRACT

The effects of the antidepressant venlafaxine (VEN-225 mg daily) and transdiagnostic cognitive behavioral treatment (CBT) alone and in combination on alcohol intake in subjects with co-morbid alcohol use disorders (AUDs) and anxiety disorders were compared. Drinking outcomes and anxiety were assessed for 81 subjects treated for 11 weeks with one of 4 conditions: 1) VEN-CBT, 2) VEN-Progressive Muscle Relaxation therapy (PMR), 3) Placebo (PLC)-CBT and 4) a comparison group of PLC-PMR. For subjects who reported taking at least one dose of study medication, the Time  $\times$  Group interaction was significant for percent days of heavy drinking and drinks consumed per day. For the measure of percent days heavy drinking, the paired comparison of PLC-CBT versus PLC-PMR group indicated that the PLC-CBT group had greater drinking reductions, whereas other groups were not superior to the comparison group. In Week 11, the proportion of subjects in the PLC-CBT group that had a 50% reduction from baseline in percent days heavy drinking was significantly greater than those in the comparison group. Of the 3 “active treatment” groups only the PLC-CBT group had significantly decreased heavy drinking when contrasted to the comparison group. This finding suggests that the transdiagnostic CBT approach of Barlow and colleagues may have value in the management of heavy drinking in individuals with co-morbid alcoholism and anxiety.

View metadata, citation and similar papers at [core.ac.uk](http://core.ac.uk)

brought to you by CORE

provided by Elsevier - Publisher Connector

## Introduction

Alcohol use disorders (AUDs) have been reported to occur with a 12-month prevalence of almost 9% of the adult population in the United States (Grant et al., 2004; Hasin, Stinson, Ogburn, & Grant, 2007). In excess of 33% of treatment seeking individuals with an AUD may have at least one concurrent independent anxiety

disorder (Grant et al., 2004). Panic and social phobia are both predictors of later alcohol use problems in adolescents and young adults (Zimmermann et al., 2003). Recent work suggests increases in the number of anxiety and other internalizing disorders, including depression and dysthymia, are directly related to increases in the prevalence of alcohol dependence (Kushner et al., 2012).

The results of several studies suggest that the existence of a co-morbid anxiety disorder can have a significant influence on the outcome of treatment of AUDs. In one study, social anxiety limited the willingness of individuals with AUDs to seek some forms of treatment for their drinking problems (Book, Thomas, Dempsey, Randall, & Randall, 2009). In another investigation, the severity of anxiety symptoms predicted recurrence of alcohol dependence in remitted patients (Boschloo et al., 2012). Phobic anxiety disorders

\* Corresponding author. Boston University School of Medicine, Suite 914, Doctors Office Building, 720 Harrison Avenue, Boston, MA 02118, United States.

E-mail address: [dciraulo@bu.edu](mailto:dciraulo@bu.edu) (D.A. Ciraulo).

also have been reported to predict shorter duration of treatment and discontinuation of treatment (Haver & Gjestad, 2005). Finally, there is evidence that social phobia is a predictor of return drinking after completion of treatment and panic disorder is a predictor of post-treatment alcohol dependence (Kushner et al., 2005).

Based on this empirical and theoretical literature, treatments for alcohol dependence that target anxiety as a mediator of treatment gains and/or relapse are appealing. Empirical evaluations of anxiety-focused treatments among substance-dependent patients (including alcoholics) have yielded mixed results. Several studies have called into question the utility of this approach (Bowen, D'Arcy, Keegan, & Senthilselvan, 2000; Ormrod & Budd, 1991; Schädé et al., 2005). In contrast, other researchers have reported that addressing symptoms of anxiety could be important for the treatment of alcoholism (Fals-Stewart & Schafer, 1992; Modesto-Lowe & Kranzler, 1999).

In addition to behavioral therapies some investigators have examined the use of selective serotonin reuptake inhibitors (SSRIs), which have anxiolytic effects, in the treatment of alcohol use disorders in individuals with co-morbid anxiety disorders. In one study, although anxiety symptoms improved in subjects treated with the SSRI paroxetine, alcohol consumption was not meaningfully altered (Thomas, Randall, Book, & Randall, 2008). In another investigation, the addition of the SSRI fluvoxamine to the treatment regime of cognitive behavioral treatment (CBT) in abstinent subjects who also received an intensive psychological relapse prevention program did not lead to better outcomes with respect to reduction in either alcohol intake or severity of anxiety (Schädé et al., 2005).

The role played by noradrenergic systems in both AUD and anxiety remains to be more fully delineated. There is evidence, however, of the involvement of these systems in both AUDs (Kash, 2012; Smith and Aston-Jones, 2008) and anxiety disorders (Bremner, Krystal, Southwick, & Charney, 1996; Dell'Osso, Buoli, Baldwin, & Altamura, 2010; Rasmussen, Wilkinson, & Raskind, 2006). Thus, agents that modify the activity of brain noradrenergic systems may be value in the management of co-morbid AUD and anxiety disorders. The present study examined the use of the NSRI (norepinephrine serotonin reuptake inhibitor) antidepressant venlafaxine for this purpose. Venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), are potent inhibitors of both norepinephrine and serotonin uptake and weak inhibitors of dopamine reuptake. It is of particular interest that the chronic administration of venlafaxine does not alter basal levels of norepinephrine within the prefrontal cortex, but does significantly lower the amount of this neurotransmitter released by a stressor such as foot shock (Dazzi et al., 2002). Chronic administration of venlafaxine has also been found to desensitize frontal cortical  $\beta$ -adrenoreceptor-coupled adenylate cyclase systems in animals selectively depleted of serotonin (Nalepa et al., 1998). These results indicate that treatment with venlafaxine can reduce the activity of noradrenergic receptor systems in certain conditions.

Several studies support the efficacy of venlafaxine in generalized anxiety disorder (Allgulander, Hackett, & Salinas, 2001; Gelenberg et al., 2000; Rickels, Pollack, Sheehan, & Haskins, 2000), panic disorder (Kjernisted & McIntosh, 2007; Liebowitz, Asnis, Mangano, & Tzanis, 2009), social phobia (Stein, Pollack, Bystritsky, Kelsey, & Mangano, 2005), and obsessive-compulsive disorder (Denys, van der Wee, van Meegen, & Westenberg, 2003; Grossman & Hollander, 1996). The objective of the present investigation was to determine whether venlafaxine administered alone or in combination with CBT using the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) developed by Barlow et al. (Barlow, Allen, & Choate, 2004; Barlow et al., 2011) would reduce alcohol intake and anxiety compared to either CBT

in combination with placebo (PLC) or PLC in combination with a "control" behavioral therapy, i.e. progressive muscle relaxation (PMR). For safety reasons all subjects were provided with an initial platform treatment of motivational enhancement therapy (MET), and were required to achieve four days of abstinence prior to randomization to reduce the potential for alcohol–venlafaxine interactions. The primary study hypothesis was that in comparison to the PLC-PMR treatment condition, the other treatment combinations would produce greater decreases during the treatment period in both alcohol consumption and anxiety. It was also hypothesized that the combination of venlafaxine and CBT would show greater improvements in decreasing alcohol consumption and anxiety than did these treatments when they were administered alone.

## Methods

Men and women were recruited into an outpatient anxiety treatment program via radio, web, and newspaper advertisements. Telephone screenings determined initial eligibility, and potential research participants were invited to the Center for Anxiety and Related Disorders at Boston University for a more extensive assessment of alcohol use and emotional symptoms.

Inclusion criteria for subject eligibility included: 1) DSM-IV diagnosis of alcohol abuse or dependence (alcohol use disorder: AUD) and a diagnosis of anxiety disorder (panic disorder, social phobia, or generalized anxiety disorder); 2) minimum age of 18 years; and 3) expressed desire to stop drinking alcohol completely or to reduce alcohol consumption with the possible long-term goal of abstinence. Exclusion criteria were: 1) DSM-IV diagnosis of bipolar disorder, schizophrenia, bulimia/anorexia, dementia, or other substance dependence, with the exception of nicotine, marijuana, and caffeine dependence; 2) medical contraindication to the use of venlafaxine; 3) currently taking anti-craving agents, anti-depressant medications, or medication known to reduce anxiety or alcohol consumption; 4) ongoing concurrent treatment for alcohol problems; 5) currently taking medication that has significant interactions with venlafaxine; 6) previously received venlafaxine; 7) currently prescribed medication with known abuse potential; and 8) having experienced severe depression or suicidal behaviors in the past 30 days.

The objective of this study was to compare the efficacy and safety of using venlafaxine and CBT to facilitate abstinence from alcohol consumption in individuals with co-morbid AUDs and anxiety disorders, as compared to combined treatment with placebo and PMR, the control treatment condition. The flow diagram for this study is presented in Fig. 1. This study, with respect to medication therapy, followed a double-blind, randomized, placebo-controlled study design.

All procedures used in this study were approved by the Boston University and Boston University Medical Center's Institutional Review Boards (IRBs), as well as the Central Texas Veterans Health Care System IRB. Subjects provided informed consent in accordance with IRB requirements. Participants who were unable to continue the drug treatment due to adverse effects were discontinued from the medication but continued to attend clinic for psychological treatment and assessment.

Following telephone screening, subjects completed an in-clinic baseline assessment to determine eligibility for inclusion in the study. Eligible subjects were assigned to a counselor who provided MET (Miller, 2004) to aid the subject in achieving an initial period of four days of complete abstinence from alcohol (as a safety precaution due to 50% chance of receiving venlafaxine). MET feedback was given based on normative data published in the Combined Behavioral Intervention Manual.




Fig. 1. Study flow diagram.

The target dose of MET varied from two to four sessions depending upon the client's desire and ability to achieve the required period of initial abstinence. These sessions were completed within two to four weeks on average. Once subjects had achieved the four day period of abstinence they completed a second baseline assessment in which eligibility was re-assessed. Eligible subjects were then randomized to receive one of four treatment conditions: 1) Venlafaxine plus individualized CBT (VEN-CBT); 2) Placebo medication plus CBT (PLC-CBT); 3) Venlafaxine plus PMR (VEN-PMR); or 4) Placebo medication plus PMR (PLC-PMR). Each treatment condition included a 7 day placebo run-in, and a 10 week trial of venlafaxine or placebo followed by a 2-week taper. Individual CBT was conducted in a standardized fashion, following the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) developed by Barlow and colleagues (Barlow et al., 2004, 2011). The UP is a transdiagnostic, emotion-focused CBT that emphasizes the adaptive, functional nature of emotions, and seeks to identify and correct maladaptive attempts to regulate emotional experiences. Development of this protocol began with the distillation of key principles from traditional empirically-supported CBT treatments integrated with innovations from the field of emotion science, incorporating and addressing deficits in emotion regulation common in emotional disorders (for discussion on the development of the UP, see Wilamowska et al., 2010). In the PMR condition, participants were told that PMR would be taught in order to help them decrease stress and negative emotions. The PMR conditions consisted of training in full-body muscle relaxation, as well as cue-controlled muscle relaxation. Eleven sessions of either

CBT or PMR were administered, each of which was approximately 50–60 min long.

Subjects received either a sustained release formulation of venlafaxine (Effexor XR) or matched placebo capsules. Active medication capsules each contained a 75 mg dose of venlafaxine. Medications were supplied in identical appearing capsules. A maintenance dose of 225 mg of venlafaxine was set as the target for subjects selected to receive active medication. This dose has been shown to have efficacy in clinical trials of several anxiety disorders including general anxiety disorder (Rickels et al., 2000), panic disorder (Pollack et al., 2007), and social anxiety disorder (Liebowitz, Gelenberg, & Munjack, 2005). In vitro evidence suggests that venlafaxine has greater affinity for the serotonin as opposed to the norepinephrine neuronal transporter (NET) proteins (Roseboom & Kalin, 2000). These results indicate a dose of venlafaxine in the range of 225 mg would be needed to elevate brain concentrations of this drug and its active metabolite *O*-des-methylvenlafaxine to levels sufficient to produce significant inhibition of NETs.

Subjects received one placebo capsule daily during the first study week. In the second study week, one capsule of either venlafaxine or placebo was provided daily to subjects. In Week 3 two medication capsules were administered to subjects daily, and the maintenance of 225 mg of venlafaxine or 3 placebo capsules were to be taken daily thereafter. The study psychiatrists were allowed to decrease the dose of medications received by subjects when it was needed to reduce adverse drug effects. Pill counts were conducted at each visit to encourage medication adherence. After completion of Study Week 11, subjects' medications were reduced over a 2-week period by weekly reductions to a dose of two then one capsule daily.

#### Assessments and measures

Anxiety and depression were measured using 5 instruments. The clinician-administered Anxiety Disorders Interview Schedule-IV: Lifetime Version (ADIS-IV-L; DiNardo, Brown, & Barlow, 1994) was used to assess anxiety disorders, depressive disorders, and AUD. The Anxiety Sensitivity Index (ASI; Reiss, Peterson, Gursky, & McNally, 1986) was used to assess fears that anxiety symptoms would have negative somatic, mental, or social consequences. The Depression Anxiety Stress Scales (DASS; Lovibond & Lovibond, 1995) assessed depression, anxiety and stress responses. Finally, the Hamilton Anxiety Rating Scale (Hamilton, 1959) and Hamilton Depression Rating Scale (Hamilton, 1960) were clinician-administered to assess symptoms of anxiety and depression, respectively.

Three measures were used to assess alcohol use and craving. The Alcohol Timeline Followback (TLFB; Sobell & Sobell, 1992) was utilized to estimate participants' daily drinking during the 90 day period that preceded screening and at the beginning of each psychotherapy session. The Alcohol Dependence Scale (ADS; Skinner & Allen, 1982) was used to assess the severity of alcohol dependence within the last 12 months, and the Craving Desire Scale (CDS) is a 3-item scale (namely, "1. I do want to drink now", "2. I crave a drink right now", "3. I have a desire for a drink right now") that was used to identify the degree of current alcohol craving, with responses provided on a Likert-scale. A maximum score of 21 could be obtained on this scale.

Participants were given a breathalyzer test and a blood pressure test at psychotherapy sessions. CDS, DASS and TLFB data were obtained prior to every treatment session. HAM-D and HAM-A data were collected for behavioral treatment Sessions 1, 4, and 8. Treatment sessions typically occurred during the corresponding study week, but in some cases, because of missed appointments behavioral treatment sessions took place in subsequent weeks.

Follow-up assessment sessions similar to the baseline assessment sessions were conducted by a research assistant one week after the completion of the treatment protocol, then subsequently at three, six, nine, and 12 months.

#### Data analysis

An intent-to-treat approach to analysis was used for this study. A second analysis was performed for alcohol drinking variables for subjects who reported taking at least one dose of study medication. Demographic and diagnostic data are presented as means ( $\pm$  standard deviations), subject numbers, or as frequencies for each treatment group. Treatment group means were also determined for other data used to characterize subjects including the ADS. The total number of subjects meeting diagnostic criteria for AUD and anxiety disorders was compiled. Baseline values for data with continuous variables for each group were compared using one-way analysis of variance (ANOVA). Comparisons of frequency data for the groups were performed using chi-square tests. Adverse effects were analyzed by pooling data into two groups based on whether a subject received venlafaxine or placebo. Between group comparisons were performed for moderate to severe adverse effects that were rated as being medication related. The Fisher's exact test was used for group comparisons of adverse effects.

The patterns of subjects' alcohol consumption were determined using TLFB derived values for percent days drinking, percent days heavy drinking, and mean drinks consumed per day. Weekly means were determined for these variables for the treatment and post-treatment periods, while a single mean for these variables was found for the 90 day-long pre-screening period. The percentage of subjects for each treatment group reporting complete abstinence during the last 5 weeks of the treatment period i.e. Study Weeks 7–11, was determined based on the available reported data from each subject. It was assumed that subjects for whom TLFB was not available for any Study Week during this period were not abstinent.

Treatment group drinking variables for both the treatment and post-treatment data sets were analyzed using a two-way repeated measures mixed models analysis (SAS version 9.2) with pre-screening values used as covariates where appropriate. Study week served as the within subject factor, while treatment condition was the between group factor. Drinking data for the drug treatment period were analyzed using data for the placebo run-in week and for the last 5 weeks of the treatment period. The assessment period using the last 5 weeks of medication administration was determined a priori and is consistent with current NIAAA studies of medications that are expected to have a delayed action in alcoholism (Litten RA, personal communication). A second analysis was conducted for a comparison of the placebo run-in week drinking data with data obtained for the first week of the follow-up period. Values for percentages of abstinent subjects in each group were compared using chi square tests.

Repeated measures mixed models analyses were also used to evaluate all treatment period data obtained for the CDS, DASS, HAM-A and HAM-D. Behavioral treatment Session, i.e. the particular therapy session prior to which assessments were administered, was used as the within subject factor for these analyses. When needed, within group time related changes between behavioral treatment Session 1 and Session 11 values were compared using paired *t*-tests for model generated least squares means. An  $\alpha$  value of less than 0.05 was considered to be significant. When several comparisons were made the appropriate significance level was determined based on the Dunn-Sidak procedure. For 3 comparisons an unadjusted  $\alpha$  value of less than 0.017 was regarded as being significant.

**Table 1**  
Subject description.

	VEN-CBT	PLC-CBT	VEN-PMR	PLC-PMR
N	24	21	14	22
Females	6	4	3	5
African American	2	1	0	2
White	21	18	12	19
Other	1	2	2	1
Alcohol dependence	23	16	14	20
Alcohol abuse	1	5	0	2
Panic disorder	2	2	3	1
GAD	18	14	8	15
Social phobia	11	10	7	13

## Results

### Subjects and subject compliance and motivation

The number of subjects assessed in each step of the study are shown in Fig. 1. Not every subject completed the full course of behavioral therapy during the 12 week medication treatment period. These individuals received the balance of this therapy following the medication treatment period. Follow-up data was obtained after the completion of both medication and behavioral treatments.

Subjects' characteristics including mean ages, race, alcohol use and anxiety diagnoses are presented in Table 1. There were no significant differences between the treatment groups with respect to any of the variables presented in the table. Significant differences amongst groups were not found for baseline ASI, HAM-A, HAM-D scores, the DASS subscale scores, or baseline measures of alcohol consumption (Table 2).

Medication compliance based on pill count was not significantly different among the four treatment groups. Patients in three of the treatment groups had medication compliance rates above 95%: VEN-CBT: 96.89% [7.15]; PLC-CBT: 97.06% [7.41]; PLC-PMR: 95.39% [9.62] while the VEN-PMR group had a compliance rate of 88.70% [24.41]. Three subjects who, although randomized, reported not taking even a single dose of study medication.


### Alcohol consumption

The mean weekly percent days heavy drinking included in the analysis are presented in Fig. 2 for the PLC-CBT and PLC-PMR treatment groups. In the intent to treat analysis the Time  $\times$  Group interaction was found to be significant for the number of drinks consumed per day [ $F(15, 37) = 1.73$ ;  $p = 0.044$ ] and approached significance for the percent days heavy drinking [ $F(15, 337) = 1.7$ ;  $p = 0.058$ ]. In a second analysis, in which data for three subjects who reported no use of any study medication or placebo were excluded, the Time  $\times$  Group interaction was significant for both number of drinks consumed per day [ $F(15, 327) = 1.85$ ;  $p = 0.027$ ] and the percent days heavy drinking [ $F(15, 327) = 1.7$ ;  $p = 0.047$ ]. For the three paired comparisons between each "active" treatment group and the PLC-PMR group for percent days heavy drinking, only the comparison with the PLC-CBT group

**Table 2**  
Means (SD) obtained for ADS scores and percent days drinking, percent days heavy drinking, and mean drinks per day for the 90 day-long pre-screening period.

	VEN-CBT	PLC-CBT	VEN-PMR	PLC-PMR
ADS scores	15.0 (7.6)	15.8 (7.7)	16.6 (6.6)	16.1 (5.9)
Percent days drinking	72.0 (24.5)	76.0 (25.6)	88.1 (12.7)	76.5 (25.8)
Percent days heavy drinking	63.1 (28.0)	59.1 (33.7)	76.9 (19.1)	67.2 (28.6)
Drinks per day	8.4 (6.5)	7.0 (4.6)	9.6 (4.3)	9.7 (7.5)






**Fig. 2.** Intent to treat data for weekly mean percent days heavy drinking for PLC-CBT and PLC-PMR treatment groups for study weeks included in the analysis, i.e. Week 1 (the Placebo Re-In Week) and Weeks 7–11.  $p = 0.01$  for the Time  $\times$  Group interaction for paired comparisons in both the intent to treat analysis and the analysis of data for subjects who used at least one dose of medication.

was found to have a significant Time  $\times$  Group interaction ( $p = 0.01$ ) after correction for multiple comparisons in *both analyses*. None of the other alcohol outcome measures differed significantly between groups in the mixed models analysis. In a post-hoc analysis the proportion of subjects with a 50% reduction from prescreening values in the percent days heavy drinking in week 11 were significant ( $p = 0.01$ ) only for the comparison between the PLC-CBT group (90%) and PLC-PMR (53%). The number of subjects who were abstinent during the entire last half of the drug treatment period were two for the VEN-CBT group, four for the PLC-CBT group, three for the VEN-PMR group, and one for the PLC-PMR group. Pairwise comparisons were not significant for comparisons of the proportion abstinent subjects in the groups between the PLC-PMR group and any of the three other groups.

#### Anxiety, depression, craving measures

Time effects, but not the Group or the Time  $\times$  Group effects, were significant for the anxiety [ $F(10, 242) = 5.01$ ;  $p < 0.0001$ ] (see Fig. 3), depression [ $F(9, 211) = 4.7$ ;  $p < 0.0001$ ], and stress [ $F(9, 202) = 12.2$ ;  $p, 0.0001$ ] subscales of the DASS obtained for the treatment period [see Fig. 3]. For the DASS anxiety subscale, model generated least squares mean values for the PLC-CBT, VEN-PMR and PLC-PMR groups were significantly lower for behavioral treatment Session 11 as compared to Session 1 (See Fig. 3). Values for the stress subscale of the DASS were significantly less for Session 11 versus Session 1 for VEN-CBT [from 16.7 (7.6) to 8.1 (4.6)], PLC-CBT [from 19.2 (9.1) to 9.6 (7.9)], VEN-PMR [from 21.5 (11.3) to 4.1 (7.9)] and PLC-PMR [from 16.6 (8.2) to 11.2 (11.1)] groups. The Session 1–Session 11 comparisons were significant for the depression subscale of the DASS only for PLC-CBT [from 12.8 (10.7) to 6.6 (7.6)] and VEN-PMR [from 16.3 (12.5) to 6.1 (10.0)] groups, but again, as indicated above, the Time  $\times$  Group interaction was not significant for this measure.

For the HAM-A scale, the Time effects, but not the Group or the Time  $\times$  Group effects, were found to be significant [ $F(2, 90) = 16.4$ ;  $p < 0.0001$ ]. The least squares means for the HAM-A scale declined significantly from Session 1 to Session 8 for the PLC-CBT [from 14.2 (7.3) to 9.1 (5.5)] and VEN-PMR [from 16.5 (6.8) to 7.9 (5.5)]



**Fig. 3.** Mean DASS-A anxiety (subscale scores obtained for Study Weeks 1–11 for each of the treatment groups. VEN-CBT PLC-CBT VEN-PMR PLC-PMR.

treatment groups, but not for the VEN-CBT [from 13.5 (5.9) to 9.8 (6.9)] or the PLC-PMR [from 12.9 (4.1) to 9.1 (4.2)] groups. The Time effect was also significant for the HAM-D [ $F(2, 80.4) = 8.8$ ;  $p = 0.0003$ ]. Session 1 to Session 8 comparisons for HAM-D least squares means were significant for the VEN-PMR group [from 13.0 (7.2) to 5.9 (5.60)], but not the VEN-CBT [from 12.0 (5.7) to 8.8 (6.6)], PLC-CBT [from 11.7 (6.0) to 8.5 (4.6)], or PLC-PMR [from 13.6 (5.0) to 10.0 (6.2)] groups. Group effects and Time  $\times$  Group interactions were not significant for the CDS measure of craving obtained during the treatment period. The Time effect was significant for this analysis [ $F(10, 271) = 3.9$ ;  $p < 0.0001$ ]. The decrease in CDS least squares mean values from Session 1 to Session 11 was significant only for the VEN-CBT group [ $p = 0.011$ ; from 8.6 (6.0) to 4.2 (1.9)] and for the PLC-PMR group ( $p = 0.004$ ), with scores declining from 7.5 (5.1) to 4.3 (2.7).

#### Adverse effects

The proportion of subjects experiencing dry mouth was significantly greater ( $p = 0.005$ ) in the venlafaxine group (39.5%) than in the placebo group (11.6%). Complaints of sexual dysfunction occurred with significantly greater frequency ( $p = 0.001$ ) in the venlafaxine (34.2%) than in the placebo group (4.7%). Of note is that suicidal ideation occurred in one subject in the venlafaxine group and in none of the placebo patients. Although not significantly different, the proportion of subjects experiencing anorexia, insomnia, and restlessness was twice as high in the venlafaxine group (as compared to the placebo group).

#### Discussion

In the present study, subjects in the CBT-PLC group had greater reductions in percent days heavy drinking in contrast to the PLC-PMR comparison group. In contrast, to the hypotheses that venlafaxine alone or CBT and active medication would significantly decrease alcohol consumption neither VEN-CBT nor the VEN-PMR was superior to the placebo group on any alcohol outcome measure. The actions of venlafaxine alone on alcohol consumption were similar to those of the SSRI's paroxetine (Schadé et al., 2005) and fluvoxamine (Thomas et al., 2008) in the

treatment of AUDs in individuals with co-morbid anxiety disorders in previous studies.

Anxiety, as measured by the anxiety subscale of the DASS, decreased significantly over the treatment period in the PLC-CBT, VEN-PMR, and PLC-PMR groups. For each group, scores for DASS stress subscales declined significantly across the treatment period, with no group differences being detected. As measured by the HAM-A, anxiety also decreased significantly from treatment session one to eight in both the PLC-CBT and VEN-PMR groups (but not PLC-PMR) with no differences between groups. Drinking was only decreased in the PLC-CBT group, suggesting a possible dissociation between changes in anxiety and in drinking. The finding that anxiety was not significantly reduced in the VEN-CBT group compared to the PLC-PMR group is consistent with other evidence that the addition of venlafaxine to CBT did not enhance the effects of CBT alone for the treatment of generalized anxiety disorder (Crits-Christoph et al., 2011).

One limitation of the present study is the small size of the treatment groups. A major consequence of this deficiency was that subject sample size became diminished during the follow-up period to the point where it may have precluded meaningful between group comparisons in this period. A second major limitation was the failure of our randomization procedure to lead to the placement of equivalent numbers of subjects into each treatment group. This resulted from our use of pre-determined randomization of subjects based on their original assigned subject number and an unexpected disparity in percentage of individuals who were able to progress from MET therapy to the treatment phase of the study amongst the subjects assigned to the difference treatment groups.

The results of this study indicate venlafaxine is not superior to placebo in its effects on alcohol consumption or anxiety in subjects with co-morbid AUD and anxiety disorders. In contrast, CBT alone may be of value in assisting individuals with co-morbid AUD and anxiety disorders in reducing heavy drinking. We observed a significant reduction in anxiety in the absence of a similar finding for alcohol consumption. This finding contradicts the notion that lessening anxiety symptoms necessarily leads to better control of drinking behavior. The goal of the Unified Protocol in this study was not to directly treat the mood symptoms of each disorder, but rather teach broad skills that address emotional regulation problems that underlie a cluster of internalizing disorders. This transdiagnostic approach is in part intended to reduce maladaptive responses to intense affect without specifically reducing or eliminating this affect. The present findings suggest transdiagnostic treatment that addresses emotional regulation problems may be of value as a tool for the management of heavy drinking. Future studies are necessary to replicate our findings, and should involve larger samples sizes and comparisons with medications that decrease anxiety and alcohol consumption.

## Acknowledgments

This work was supported by a grant R01-AA013727-awarded to DAC, K23-DA016376 awarded to SBM, and K23DA016138 awarded to BWK. The authors would like to thank Ann Marie Ciraulo RN for her critical review of the data and Ms. Michele Procida for preparation of the manuscript.

## References

Allgulander, C., Hackett, D., & Salinas, E. (2001). Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. *British Journal of Psychiatry*, 179, 15–22.

Barlow, D. H., Allen, L. B., & Choate, M. L. (2004). Toward a unified treatment for emotional disorders. *Behaviour Therapy*, 35, 205–230.

Barlow, D. H., Farchione, T. J., Fairholme, C. P., Ellard, K. K., Boisseau, C. L., Allen, L. B., et al. (2011). *The unified protocol for transdiagnostic treatment of emotional disorders: Therapist guide*. New York: Oxford University Press.

Book, S. W., Thomas, S. E., Dempsey, J. P., Randall, P. K., & Randall, C. L. (2009). Social anxiety impacts willingness to participate in addiction treatment. *Addictive Behaviors*, 34(5), 474–476.

Boschloo, L., Vogelzangs, N., van den Brink, W., Smit, J. H., Beekman, A. T., & Penninx, B. W. (2012). Predictors of the 2-year recurrence and persistence of alcohol dependence. *Addiction*, 107(9), 1639–1640.

Bowen, R. C., D'Arcy, C., Keegan, D., & Senthilselvan, A. (2000). A controlled trial of cognitive behavioral treatment of panic in alcoholic inpatients with co-morbid panic disorder. *Addictive Behaviors*, 25(4), 593–597.

Bremner, J. D., Krystal, J. H., Southwick, S. M., & Charney, D. S. (1996). Noradrenergic mechanisms in stress and anxiety preclinical studies. *Synapse*, 23(1), 28–38.

Crits-Christoph, P., Newman, M. G., Rickels, K., Gallop, R., Gibbons, M. B., Hamilton, J. L., et al. (2011). Combined medication and cognitive therapy for generalized anxiety disorder. *Pharmacogenomics Journal*, 25, 1087–1095.

Dazzi, L., Vignone, V., Seu, E., Ladu, S., Vacca, G., & Biggio, G. (2002). Inhibition by venlafaxine of the increase in norepinephrine output in rat prefrontal cortex elicited by acute stress or by the anxiogenic drug FG 7142. *Journal of Psychopharmacology*, 16(2), 125–131.

Dell'Osso, B., Buoli, M., Baldwin, D. S., & Altamura, A. C. (2010). Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy. *Human Psychopharmacology*, 25(1), 17–29.

Denys, D., van der Wee, N., van Megen, H. J., & Westenberg, H. G. (2003). A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. *Journal of Clinical Psychopharmacology*, 23(6), 568–575.

DiNardo, P. A., Brown, T. A., & Barlow, D. H. (1994). *Anxiety disorders interview schedule for DSM IV: Lifetime version (ADIS-IV-L)*. New York: Oxford University Press.

Fals-Stewart, W., & Schafer, J. (1992). The treatment of substance abusers diagnosed with obsessive-compulsive disorder: an outcome study. *Journal of Substance Abuse Treatment*, 9(4), 365–370.

Gelenberg, A. J., Lydiard, R. B., Rudolph, R. L., Aguiar, L., Haskins, J. T., & Salinas, E. (2000). Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. *The Journal of the American Medical Association*, 283(23), 3082–3088.

Grant, B. F., Stinson, F. S., Dawson, D. A., Chou, S. P., Dufour, M. C., Compton, W., et al. (2004). Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions. *Archives of General Psychiatry*, 61(8), 807–816.

Grossman, R., & Hollander, E. (1996). Treatment of obsessive-compulsive disorder with venlafaxine. *American Journal of Psychiatry*, 153(4), 576–577.

Hamilton, M. (1959). The assessment of anxiety states by rating. *British Journal of Medical Psychology*, 32(1), 50–55.

Hamilton, M. A. (1960). Rating scale for depression. *Journal of Neurology, Neurosurgery & Psychiatry*, 23, 56–62.

Hasin, D. S., Stinson, F. S., Ogburn, E., & Grant, B. F. (2007). Prevalence, correlates, disability, and co-morbidity of DSM-IV alcohol abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. *Archives of General Psychiatry*, 64(7), 830–842.

Haver, B., & Gjestad, R. (2005). Phobic anxiety and depression as predictor variables for treatment outcome. A LISREL analysis on treated female alcoholics. *Nordic Journal of Psychiatry*, 59(1), 25–30.

Kash, T. L. (2012 Jun). The role of biogenic amine signaling in the bed nucleus of the stria terminals in alcohol abuse. *Alcohol*, 46(4), 303–308.

Kjemistad, K., & McIntosh, D. (2007). Venlafaxine extended release (XR) in the treatment of panic disorder. *Therapeutics and Clinical Risk Management*, 3(1), 59–69.

Kushner, M. G., Abrams, K., Thuras, P., Hanson, K. L., Brekke, M., & Sletten, S. (2005). Follow-up study of anxiety disorder and alcohol dependence in co-morbid alcoholism treatment patients. *Alcoholism Clinical and Experimental Research*, 29(8), 1432–1443.

Kushner, M. G., Wall, M. M., Krueger, R. F., Sher, K. J., Maurer, E., Thuras, P., et al. (2012). Alcohol dependence is related to overall internalizing psychopathology load rather than to particular internalizing disorders: evidence from a national sample. *Alcoholism Clinical and Experimental Research*, 36(2), 325–331.

Liebowitz, M. R., Asnis, G., Mangano, R., & Tzanis, E. (2009). A double-blind, placebo-controlled, parallel-group, flexible-dose study of venlafaxine extended release capsules in adult outpatients with panic disorder. *Journal of Clinical Psychiatry*, 70(4), 550–561.

Liebowitz, M. R., Gelenberg, A. J., & Munjack, D. (2005). Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. *Archives of General Psychiatry*, 62(2), 190–198.

Lovibond, P. F., & Lovibond, S. H. (1995). The structure of negative emotional states: comparison of the depression, anxiety stress scales (DASS) with the Beck depression and anxiety inventories. *Behaviour Research and Therapy*, 33, 335–343.

Miller, W. R. (Ed.). (2004). *Combine monograph series: Vol. 1. Combined behavioral intervention manual: A clinical research guide for therapists treating people with alcohol abuse and dependence*. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism. DHHS No. 04–5288.

Modesto-Lowe, V., & Kranzler, H. R. (1999). Diagnosis and treatment of alcohol-dependent patients with co-morbid psychiatric disorders. *Alcohol Research & Health*, 23(2), 144–149.

Nalepa, I., Manier, D. H., Gillespie, D. D., Rossby, S. P., Schmidt, D. E., & Sulser, F. (1998). Lack of beta adrenoceptor desensitization in brain following the dual

- noradrenaline and serotonin reuptake inhibitor venlafaxine. *European Neuropsychopharmacology*, 8(3), 227–232.
- Ormrod, J., & Budd, R. (1991). A comparison of two treatment interventions aimed at lowering anxiety levels and alcohol consumption amongst alcohol abusers. *Drug and Alcohol Dependence*, 27(3), 233–243.
- Pollack, M., Mangano, R., Entsuah, R., Tzanis, E., Simon, N. M., & Zhang, Y. (2007). A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. *Psychopharmacology (Berl)*, 194(2), 233–242.
- Rasmussen, D. D., Wilkinson, C. W., & Raskind, M. A. (2006). Chronic daily ethanol and withdrawal: 6. Effects on rat sympathoadrenal activity during “abstinence”. *Alcohol*, 38(3), 173–177.
- Reiss, S., Peterson, R. A., Gursky, D. M., & McNally, R. J. (1986). Anxiety sensitivity, anxiety frequency and the prediction of fearfulness. *Behaviour Research and Therapy*, 24(1), 1–8.
- Rickels, K., Pollack, M. H., Sheehan, D. V., & Haskins, J. T. (2000). Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. *American Journal of Psychiatry*, 157(6), 968–974.
- Roseboom, P. H., & Kalin, N. H. (2000). Neuropharmacology of venlafaxine. *Depress Anxiety*, 12(Suppl. 1), 20–29.
- Schadé, A., Marquenie, L. A., van Balkom, A. J., Koeter, M. W., de Beurs, E., van den Brink, W., et al. (2005). The effectiveness of anxiety treatment on alcohol-dependent patients with a co-morbid phobic disorder: a randomized controlled trial. *Alcoholism Clinical and Experimental Research*, 29(5), 794–800.
- Skinner, H. A., & Allen, B. A. (1982). Alcohol dependence syndrome: measurement and validation. *Journal of Abnormal Psychology*, 91(3), 199–209.
- Smith, R. J., & Aston-Jones, G. (2008). Noradrenergic transmission in the extended amygdala: role in increased drug-seeking and relapse during protracted drug abstinence. *Brain Structure and Function*, 213(1–2), 43–61.
- Sobell, L. C., & Sobell, M. B. (1992). Timeline follow-back: a technique for assessing self-reported alcohol consumption. In R. Z. Littenand, & J. P. Allen (Eds.), *Measuring alcohol consumption: Psychosocial and biological methods* (pp. 41–72). Totowa, NJ: Humana Press.
- Stein, M. B., Pollack, M. H., Bystritsky, A., Kelsey, J. E., & Mangano, R. M. (2005). Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. *Psychopharmacology (Berl)*, 177(3), 280–288.
- Thomas, S. E., Randall, P. K., Book, S. W., & Randall, C. L. (Jan 2008). A complex relationship between co-occurring social anxiety and alcohol use disorders: what effect does treating social anxiety have on drinking? *Alcoholism, Clinical and Experimental Research*, 32(1), 77–84.
- Wilamowska, Z. A., Thompson-Hollands, J., Fairholme, C. P., Ellard, K. K., Farchione, T. J., & Barlow, D. H. (2010). Conceptual background, development, and preliminary data from the unified protocol for transdiagnostic treatment of emotional disorders. *Depression and Anxiety*, 27, 882–890.
- Zimmermann, P., Wittchen, H. U., Höfler, M., Pfister, H., Kessler, R. C., & Lieb, R. (2003). Primary anxiety disorders and the development of subsequent alcohol use disorders: a 4-year community study of adolescents and young adults. *Psychologie Medicale*, 33(7), 1211–1222.